Extensive Product Profile: Understanding Brcaone 150mg Tablet Brcaone 150mg Tablet contains Olaparib, an advanced, first-in-class selective Poly (ADP-ribose) Polymerase (PARP) inhibitor. Manufactured to the highest global pharmaceutical standards by Emcure Pharmaceuticals Ltd., this targeted oral antineoplastic agent is integrated into precision-guided oncology protocols worldwide to manage complex, biomarker-specific malignancies. 1. Clinical Indications & Usage Advanced Ovarian Cancer: Used as maintenance treatment for adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. gBRCAm HER2-Negative Metastatic Breast Cancer: Indicated for patients with germline BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Metastatic Pancreatic Cancer: Deployed as a first-line maintenance therapy for adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on a minimum of 16 weeks of a first-line platinum-based chemotherapy regimen. 2. Mechanism of Action: How Brcaone Works PARP Trapping: Brcaone physically traps the PARP enzymes at the site of single-strand DNA damage. This accumulation stalls moving replication forks during cellular division, transforming manageable single-strand breaks into lethal double-strand DNA breaks. PARP Enzyme Inhibition: Olaparib selectively blocks the enzymatic activity of PARP1 and PARP2, which are crucial for repairing single-strand DNA breaks via the Base Excision Repair pathway. 3. Administration and Dosing Guide Administration Route: Brcaone 150mg is an oral tablet formulation. It must be swallowed whole with a glass of water. Do not chew, crush, dissolve, or split the tablet, as this disrupts the controlled-release delivery matrix. Food Interactions: Tablets can be taken consistently either with or without food. Standard Schedule: The standard recommended adult dosage is 300mg (two 150mg tablets) taken orally twice daily, roughly 12 hours apart, bringing the total baseline daily dose to 600mg. Dose Modifications: Treating oncologists track individual hematological tolerance closely. Dose adjustments down to 250mg or 200mg twice daily may be carried out to manage treatment-emergent toxicities. ⚠️ Safety, Side Effects, and Monitoring Bone Marrow Suppression (Myelosuppression): Severe hematological toxicities, including severe anemia, neutropenia, and thrombocytopenia, are common. Baseline and monthly Complete Blood Counts CBC are mandatory. Treatment should be held if severe cytopenia develops. MDS/AML Risks: Rare but serious cases of Myelodysplastic Syndrome MDS or Acute Myeloid Leukemia AML—some fatal—have been reported in patients receiving PARP inhibitors. Patients must be monitored for prolonged cytopenias. Common Side Effects: Nausea, vomiting, severe fatigue, diarrhea, loss of appetite, changes in taste (dysgeusia), headache, dizziness, abdominal pain, indigestion (dyspepsia), and minor elevations in serum creatinine. 📦 Storage and Handling Specifications Storage Framework: Store Brcaone 150mg tablets below 30°C (86°F) in a dry, dark, climate-controlled zone. Environmental Safeguards: Keep the tablets sealed inside their original manufacturer bottle packaging. Protect the medication from high humidity, excess moisture, and direct UV light exposure. Keep strictly out of reach of children and domestic pets. 📄 Regulatory and Compliance Documentation Authentic Manufacturer Certificate of Analysis COA Verified Batch Origin Ledger and Packaging Tracking Data Global Import-Export Authorization & Custom Clearance PRESCRIPTION MEDICINE IS: YES Clinical Disclaimer: This profile is compiled strictly for international wholesale procurement, institutional distributors, and commercial research. Brcaone 150mg Tablet is an advanced oncology drug available exclusively under clinical authorization. It must be handled, dispensed, and utilized solely under the direct guidance of a registered oncology specialist Why Choose Primecare Impex? Full Batch Traceability Global Custom Specialists Validated Bulk Capacity 📞 Contact PRIMECARE IMPEX — Bulk Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Extensive Product Profile: Understanding Braunamide 25mg Capsule Braunamide 25mg Capsule contains Lenalidomide, a highly potent, small-molecule immunomodulatory drug possessing direct antineoplastic, anti-angiogenic, and microenvironmental-disrupting actions. Manufactured to rigorous international regulatory standards by Samarth Life Sciences Pvt. Ltd., this high-strength formulation is integrated globally into complex hematology-oncology treatment protocols to treat aggressive and advanced bone marrow and lymphatic malignancies. 1. Clinical Indications & Usage Multiple Myeloma (MM): Prescribed in combination with dexamethasone as a foundational therapy for adult patients with newly diagnosed multiple myeloma (who are eligible or ineligible for transplantation) or those with relapsed or refractory disease who have progressed following at least one prior anti-myeloma regimen. Mantle Cell Lymphoma (MCL): Authorized for the treatment of adult patients with relapsed or refractory mantle cell lymphoma whose disease has progressed following two prior systemic therapies, including at least one proteasome inhibitor (such as bortezomib). Follicular Lymphoma (FL) & Marginal Zone Lymphoma (MZL): Used in combination with a rituximab regimen for adult patients with previously treated Grade 1, 2, or 3a follicular lymphoma or marginal zone lymphoma. 2. Mechanism of Action: How Braunamide Works Direct Cytotoxicity: In malignant plasma lines, the immediate depletion of Ikaros and Aiolos downregulates key oncogenic drivers (like IRF4 and c-Myc), halting cell division and inducing rapid programmed cell death (apoptosis). Anti-Angiogenesis: Braunamide cuts off the tumor's microenvironmental support structure by blocking endothelial cell migration, effectively starving the tumor of the blood supply needed for growth. Targeted Transcription Factor Degradation: This structural binding alters the ligase's surface architecture, selectively forcing the recruitment, ubiquitination, and subsequent proteasomal destruction of two essential lymphoid transcription factors 3. Administration and Dosing Guide Administration Route: Braunamide 25mg is formulated strictly as an oral capsule. It must be swallowed whole with a full glass of water at roughly the same time each day. Never break, crush, chew, or open the capsule shell. Dosing Cycles: Dosing schedules are highly customized and cycle-dependent. A standard multiple myeloma regimen involves taking 25mg orally once daily on Days 1 through 21 of repeated 28-day cycles. Dose Modifications: Treating oncologists strictly monitor absolute neutrophil and platelet counts to manage necessary dose reductions, delays, or structural interruptions. ⚠️ Safety, Side Effects, and Monitoring Embryo-Fetal Toxicity (Black Box Warning): Lenalidomide is structurally related to thalidomide and possesses a severe risk of life-threatening human birth defects or embryo-fetal death. Strict Risk Evaluation and Mitigation Strategies or equivalent global controlled safety distribution frameworks apply Severe Myelosuppression: Can induce deep hematological toxicities, including severe neutropenia (low white blood cells) and thrombocytopenia (low platelets). Baseline and weekly Complete Blood Counts are mandatory during the first two cycles (8 weeks) of therapy. Common Side Effects: Severe fatigue, diarrhea, constipation, nausea, pruritus (severe skin itching), muscle cramps, cough, dyspnea (shortness of breath), peripheral edema, dizziness, and pyrexia. 📦 Storage and Handling Specifications Storage Parameters: Store Braunamide 25mg capsules below 30°C (86°F) in a dry, dark, climate-controlled zone. Safe Handling: Retain the capsules inside their original sealed blister cards until the exact moment of administration to shield them from environmental moisture and prevent accidental skin exposure to the internal powder. Keep strictly out of reach of children and domestic animals. 📄 Regulatory and Compliance Documentation Authentic Manufacturer Certificate of Analysis COA Verified Batch Origin Ledger and Tracking Data Global Import-Export Authorization & Custom Clearance PRESCRIPTION MEDICINE IS: YES Clinical Disclaimer: This profile is compiled strictly for international wholesale procurement, institutional distributors, and commercial research. Braunamide 25mg Capsule is a specialized oncology agent available strictly under clinical prescription and authorization.. Why Choose Primecare Impex? Full Batch Traceability Global Custom Specialists Validated Bulk Capacity 📞 Contact PRIMECARE IMPEX — Bulk Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130

Extensive Product Profile: Understanding Braunamide 10mg Capsule Braunamide 10mg Capsule contains Lenalidomide, an advanced, small-molecule immunomodulatory drug possessing potent anti-angiogenic and direct antineoplastic activities. Manufactured to international regulatory quality standards by Samarth Life Sciences Pvt. Ltd., it is integrated worldwide into complex oncology and hematology treatment protocols to combat aggressive bone marrow and lymphatic malignancies. 1. Clinical Indications & Usage Multiple Myeloma (MM): Prescribed in combination with dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma, or those with relapsed/refractory disease who have failed at least one prior anti-myeloma regimen. It is also deployed globally as a single-agent continuous maintenance therapy following autologous stem cell transplantation . Myelodysplastic Syndromes (MDS): Indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a cytogenetic deletion chromosomal abnormality, with or without additional cytogenetic alterations . Mantle Cell Lymphoma (MCL): Authorized for the treatment of adult patients with relapsed or refractory mantle cell lymphoma whose disease has relapsed or progressed following at least two prior systemic therapies, one of which must include a proteasome inhibitor like bortezomib. 2. Mechanism of Action: How Braunamide Works Ubiquitin Ligase Binding: Lenalidomide directly binds to cereblon an integral component of the functional cullin-RING E3 ubiquitin ligase enzyme complex. Anti-Angiogenesis: Braunamide blocks endothelial cell migration and microvessel formation, starving tumors of the blood supply and vital nutrients needed for expansion. Dual Anti-Tumor & Immunomodulatory Response: The deletion of Ikaros and Aiolos results in a direct down-regulation of oncogenic survival pathways, inducing rapid programmed cell death (apoptosis) in malignant plasma lines. 3. Administration and Dosing Guide Administration Route: Braunamide 10mg is formulated exclusively as an oral capsule. It must be swallowed whole with a glass of water at roughly the same time each day. Never break, crush, chew, or open the capsule shell. Food Dynamics: Capsules can be taken consistently either with or without food. Renal Adjustments: Because lenalidomide is primarily cleared by the kidneys, baseline renal function panels are mandatory, and down-titrations are required for patients experiencing moderate-to-severe renal impairment. ⚠️ Safety, Side Effects, and Monitoring Embryo-Fetal Toxicity: Lenalidomide is structurally related to thalidomide and possesses severe, life-threatening risks of human birth defects or embryo-fetal death. Strict Risk Evaluation and Mitigation Strategies or equivalent global safety distribution systems apply. Hematological Toxicities (Myelosuppression): Can cause severe neutropenia (low white blood cell counts) and thrombocytopenia (low platelet counts). Baseline and weekly Complete Blood Counts are required during the initial 8 weeks of treatment. Common Side Effects: Severe fatigue, diarrhea, constipation, nausea, pruritus (severe skin itching), muscle cramps, cough, breathlessness, peripheral edema, dizziness, and low-grade pyrexia. 📦 Storage and Handling Specifications Storage Parameters: Store Braunamide 10mg capsules below 30°C (86°F) in a dry, dark, climate-controlled zone. Safe Handling: Retain the capsules inside their original sealed blister packs until the exact moment of administration to protect them from environmental humidity and accidental structural damage. Keep strictly out of reach of children and domestic animals. 📄 Regulatory and Compliance Documentation Authentic Manufacturer Certificate of Analysis Verified Batch Origin Ledger and Tracking Data Global Import-Export Authorization & Custom Clearance PRESCRIPTION MEDICINE IS: YES Clinical Disclaimer: This profile is compiled strictly for international wholesale procurement, institutional distributors, and commercial research. Braunamide 10mg Capsule is a specialized oncology agent available strictly under clinical prescription and authorization. It must be dispensed, monitored, and adjusted solely under the direction of a registered hematology-oncology specialist. Why Choose Primecare Impex? Full Batch Traceability Global Custom Specialists Validated Bulk Capacity 📞 Contact PRIMECARE IMPEX — Bulk Pharmaceutical Exporter from India [A Group of Prime Care Impex Pvt. Ltd.] 🌐 Website: www.medicineexporterfromindia.com 📧 Commercial Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Global Distributor 📲 Direct WhatsApp Line: +91 9673008130 🔗 Instant Chat Access: https://wa.me/919673008130